HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells

Virology Journal

Volumn 14, Issue 1, 2017, Pages

  Wang, Yongfang ^a   Li, Xinyu ^a   Song, Shasha ^a   Sun, Yang ^a   Zhang, Jiafen ^a   Yu, Changming ^b   Chen, Wei ^b  

^a INSTITUTE OF DERMATOLOGY   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3; Condylomata acuminata; Early gene 6; HaCaT keratinocytes; Human papillomavirus 11; Interferon

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; CYTIDINE DEAMINASE; LENTIVIRUS VECTOR; MESSENGER RNA; PROTEIN E6; RECOMBINANT INTERFERON; RECOMBINANT OMEGA INTERFERON; UNCLASSIFIED DRUG; APOBEC3A PROTEIN, HUMAN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11; INTERFERON; INTERFERON OMEGA 1; ONCOPROTEIN; PROTEIN;

AMINO ACID SUBSTITUTION; APOBEC3A; APOBEC3B GENE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA DENATURATION; E6 GENE; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HACAT CELL LINE; HUMAN PAPILLOMAVIRUS TYPE 11; IMMUNOFLUORESCENCE TEST; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; SEQUENCE ALIGNMENT; UPREGULATION; VIRUS GENE; VIRUS GENOME; WESTERN BLOTTING; CELL CYCLE; CELL LINE; CONDYLOMA ACUMINATUM; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; KERATINOCYTE; METABOLISM; MUTATION; VIROLOGY;

CELL CYCLE; CELL LINE; CONDYLOMATA ACUMINATA; CYTIDINE DEAMINASE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 11; HUMANS; INTERFERON TYPE I; KERATINOCYTES; MUTATION; ONCOGENE PROTEINS, VIRAL; PROTEINS; RNA, MESSENGER; UP-REGULATION;

EID: 85032805330     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-017-0878-2     Document Type: Article

References (36)

1. Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015;41:844-52.
2. Pizzol D, Putoto G, Chhaganlal KD. Human papillomavirus (HPV) infection: a Mozambique overview. Virusdisease. 2016;27:116-22.
3. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119-27.
4. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.
5. Tummers B, Burg SH. High-risk human papillomavirus targets crossroads in immune signaling. Viruses. 2015;7:2485-506.
6. Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21-33.
7. Bennetts LE, Wagner M, Giuliano AR, Palefsky JM, Steben M, Weiss TW. Associations of Anogenital low-risk human Papillomavirus infection with cancer and acquisition of HIV. Sex Transm Dis. 2015;42:541-4.
8. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679-91.
9. Willems L, Gillet NA. APOBEC3 interference during replication of viral genomes. Viruses. 2015;7:2999-3018.
10. Desimmie BA, Burdick RC, Izumi T, Doi H, Shao W, Alvord WG, Sato K, Koyanagi Y, Jones S, Wilson E, et al. APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res. 2016;44:7848-65.
11. Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat. 2013;20:821-8.
12. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320:230-3.
13. Siriwardena SU, Chen K, Bhagwat AS. Functions and malfunctions of mammalian DNA-cytosine Deaminases. Chem Rev. 2016;116:12688-710.
14. Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48:1330-8.
15. Kondo S, Wakae K, Wakisaka N, Nakanishi Y, Ishikawa K, Komori T, Moriyama-Kita M, Endo K, Murono S, Wang Z, et al. APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene. 2017;36:1687-97.
16. Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul AM, Kukimoto I, Muramatsu M. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol. 2014;88:1308-17.
17. Kukimoto I, Mori S, Aoyama S, Wakae K, Muramatsu M, Kondo K. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. J Med Virol. 2015;87:1754-60.
18. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550-60.
19. Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis. 2015;36:1397-406.
20. Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande PS, Podjarny A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529:541-5.
21. Wallace NA, Galloway DA. Novel functions of the human Papillomavirus E6 Oncoproteins. Annu Rev Virol. 2015;2:403-23.
22. Danielewski JA, Garland SM, McCloskey J, Hillman RJ, Tabrizi SN. Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia. PLoS One. 2013;8:e63892.
23. Wang Y, Li X, Song S, Sun Y. Expression of APOBEC3s in HaCaT keratinocytes containing the genome of human papillomavirus type 11 and regulatory function of interferon-alpha. Chin. J Dermatol. 2016;49(2):88-92.
24. Bracci L, Sistigu A, Proietti E, Moschella F. The added value of type I interferons to cytotoxic treatments of cancer. Cytokine Growth Factor Rev. 2017;36:89-97.
25. Sun Y, Li X, Song S, Wang Y, Gu H. Integrity of a HPV11 infection cell model and identification of (-)-Epigallocatechin-3-gallate as a potential HPV11 inhibitor. Oncotarget. 2016;7:37092-102.
26. Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol. 2006;99:62-70.
27. Skorvanova L, Svancarova P, Svetlikova D, Betakova T. Protective efficacy of IFN-omega AND IFN-lambdas against influenza viruses in induced A549 cells. Acta Virol. 2015;59:413-7.
28. Hagelstein J, Kist A, Stremmel W, Galle PR. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells. Arzneimittelforschung. 1998;48:343-7.
29. Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antivir Res. 2007;73:118-25.
30. Wang Y, Li X, Song S, Wu J. Development of basal-like HaCaT Keratinocytes containing the genome of human Papillomavirus (HPV) type 11 for screening of anti-HPV effects. J Biomol Screen. 2014;19:1154-63.
31. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015;89:688-702.
32. Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013;12:762-72.
33. Lyman RC, Wilson ML, Herrington CS. Cell-cycle control protein expression is disrupted in anogenital condylomata infected with low-risk human papillomavirus types. J Low Genit Tract Dis. 2008;12:224-31.
34. Reinson T, Henno L, Toots M, Ustav MJ, Ustav M. The cell cycle timing of human Papillomavirus DNA replication. PLoS One. 2015;10:e131675.
35. Fuertes MB, Woo SR, Burnett B, YX F, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67-73.
36. He X, Korytař T, Schatz J, Freuling CM, Müller T, Köllner B. Anti-lyssaviral activity of interferons κ and ω from the serotine bat, Eptesicus Serotinus. J Virol. 2014;88:5444-54.